ArticleNPJ vaccines2026
A 25-year landscape of Escherichia coli vaccine development: systematic review of human clinical studies.
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli (E. coli), especially enterotoxigenic (ETEC) and extraintestinal pathogenic (ExPEC) strains, remains a leading cause of diarrheal and systemic infections worldwide. Despite decades of extensive research, no licensed E. coli vaccine for human use is currently available. A comprehensive and updated synthesis of evidence from human clinical studies is timely. We performed a systematic review of clinical trials published between January 1, 2000, and October 24, 2024, identified through PubMed, Web of Science, Scopus, and ClinicalTrials.gov. Only original clinical studies of prophylactic vaccines were included; therapeutic. Forty-two studies met the inclusion criteria: 34 on ETEC, 6 on ExPEC, and 2 on other pathotypes. Vaccine platforms included inactivated/killed whole-cell (n = 14), subunit (n = 12), live-attenuated (n = 9), and conjugate vaccines (n = 7). Most vaccine candidates induced measurable immune responses. Among the ten trials that reported efficacy outcomes, two presented high levels of protection, six were associated with reductions in disease severity, and two demonstrated no protective effect. Safety profiles were generally favorable. By identifying patterns of success alongside persistent gaps, this review aims to inform the rational design and strategic prioritization of next-generation E. coli vaccine candidates. Progress will require standardized efficacy trials, multivalent platforms, and optimized mucosal adjuvants to advance candidates toward licensure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.